2,2-Dimethyl-7-nitro-2,3-dihydro-4H-benzo[e][1,3]oxazin-4-one

Catalog No. :
ACIGVR405
CAS No. :
1110662-18-4
Molecular Formula :
C10H10N2O4
Molecular Weight :
222.20

IUPAC Name:2,2-dimethyl-7-nitro-2,3-dihydro-4H-benzo[e][1,3]oxazin-4-one

2,2-Dimethyl-7-nitro-2,3-dihydro-4H-benzo[e][1,3]oxazin-4-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$121.00Login to see priceIn stockInquiry
100mg95%$208.00Login to see priceIn stockInquiry
250mg95%$347.00Login to see priceIn stockInquiry
1g95%$901.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2,2-Dimethyl-7-nitro-2,3-dihydro-4H-benzo[e][1,3]oxazin-4-one
IUPAC Name2,2-dimethyl-7-nitro-2,3-dihydro-4H-benzo[e][1,3]oxazin-4-one
MDL No.MFCD13152343
Molecular FormulaC10H10N2O4
Molecular Weight222.20
SMILESCC1(C)NC(=O)C2=CC=C(C=C2O1)[N+]([O-])=O
InChI KeyCZHKQCMWJAWKGO-UHFFFAOYSA-N
Synonym2,2-DIMETHYL-7-NITRO-2H-BENZO[E][1,3]OXAZIN-4(3H)-ONE;2,3-dihydro-2,2-dimethyl-7-nitro-4H-1,3-Benzoxazin-4-one;4H-1,3-Benzoxazin-4-one, 2,3-dihydro-2,2-dimethyl-7-nitro-;2,2-Dimethyl-7-nitro-2,3-dihydro-4H-benzo[e][1,3]oxazin-4-one
CAS No.1110662-18-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACIGVR405 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACIGVR405 route product structure diagram
    ACIGVR4051110662-18-4 In Stock
Inquiry

2. ACIGVR405 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACIGVR405 route product structure diagram
    ACIGVR4051110662-18-4 In Stock
Inquiry

Comments (0)